â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
       BioNXA GENOMIC ANALYSIS REPORT
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

Sample ID: demo_ecoli
Analysis Date: 2026-02-12 12:36:18
Pipeline Version: 1.0

Based on methodology from:
  Aljohani RH, et al. Genomic Characterization of Uropathogenic 
  Escherichia coli Isolates from Tertiary Hospitals in Riyadh, 
  Saudi Arabia. Int J Mol Sci. 2023;24(8):7582.

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
ANALYSIS SUMMARY
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

âœ“ Quality Control:          PASS
âœ“ Genome Assembly:           COMPLETE
âœ“ Genome Annotation:         4,986 genes predicted
âœ“ MLST Typing:               
[0;32m[2026-02-12 12:36:18][0m STEP 4: Multilocus Sequence Typing (MLST)
[0;34m[INFO][0m Using Abricate v0.9.8 with mlst database
[0;34m[INFO][0m âœ“ MLST analysis completed
[0;34m[INFO][0m   Sequence Type: ST131
ST131
âœ“ AMR Gene Detection:        Multidrug-resistant
âœ“ Virulence Factors:         UPEC pathotype confirmed
âœ“ Serotyping:                Complete
âœ“ Phylogroup:                B2 (ExPEC)

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
KEY FINDINGS
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

1. BACTERIAL IDENTIFICATION
   Species: Escherichia coli
   Pathotype: Uropathogenic E. coli (UPEC)
   Sequence Type: 
[0;32m[2026-02-12 12:36:18][0m STEP 4: Multilocus Sequence Typing (MLST)
[0;34m[INFO][0m Using Abricate v0.9.8 with mlst database
[0;34m[INFO][0m âœ“ MLST analysis completed
[0;34m[INFO][0m   Sequence Type: ST131
ST131
   Phylogenetic Group: B2

2. ANTIMICROBIAL RESISTANCE
   Profile: Multidrug-resistant (MDR)
   ESBL Producer: YES (blaCTX-M-15)
   Fluoroquinolone Resistant: YES (QRDR mutations)
   
   Resistant to:
     â€¢ Î²-lactams (including 3rd-gen cephalosporins)
     â€¢ Fluoroquinolones (ciprofloxacin)
     â€¢ Aminoglycosides (gentamicin)
     â€¢ Trimethoprim-sulfamethoxazole
     â€¢ Tetracyclines

3. VIRULENCE PROFILE
   Classification: High virulence potential
   Key factors: Type 1 fimbriae, hemolysin, siderophores
   Biofilm formation: Positive
   Capsule production: Positive

4. CLINICAL SIGNIFICANCE
   Risk Level: HIGH
   Public Health Concern: PRIORITY PATHOGEN
   
   This isolate represents a globally disseminated multidrug-
   resistant lineage of UPEC. Enhanced surveillance and strict
   infection control measures are recommended.

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
TREATMENT RECOMMENDATIONS
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

Based on genotypic resistance profile:

EFFECTIVE OPTIONS:
  âœ“ Carbapenems (Imipenem, Meropenem)
  âœ“ Nitrofurantoin (for uncomplicated UTI)
  âœ“ Fosfomycin
  âœ“ Tigecycline (reserve)

INEFFECTIVE OPTIONS (Predicted Resistance):
  âœ— Ampicillin
  âœ— Cephalosporins (including 3rd generation)
  âœ— Ciprofloxacin
  âœ— Trimethoprim-sulfamethoxazole
  âœ— Tetracyclines

CLINICAL NOTES:
  â€¢ Antimicrobial stewardship is critical
  â€¢ Consider infectious disease consultation
  â€¢ Monitor for treatment failure
  â€¢ Implement strict infection control measures

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
EPIDEMIOLOGICAL CONTEXT
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

According to Aljohani et al. (2023) study in Riyadh, Saudi Arabia:

  â€¢ ST131 prevalence: 39.6% of ESBL-producing UPEC
  â€¢ ST1193 prevalence: 12.5% (emerging lineage - FIRST REPORT)
  â€¢ Overall ESBL rate: 33.9%
  â€¢ Fluoroquinolone resistance: 77.1% of ESBL isolates
  
  Global Context:
    - ST131 is a pandemic clone
    - Disseminated worldwide (Asia, Europe, Americas, Middle East)
    - Major cause of community and hospital-acquired UTIs
    - High transmission potential

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
DATA AVAILABILITY
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

NCBI BioProject: PRJNA897916
SRA Accessions: SRR22179269-SRR22179316

Research Data:
  â€¢ 165 UPEC isolates from two Riyadh tertiary hospitals
  â€¢ 48 whole genome sequences (ESBL producers)
  â€¢ Study period: May 2019 - September 2020

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
OUTPUT FILES
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

All analysis results are available in: ./data/demo/results/demo_ecoli

  qc/                Quality control reports
  assembly/          Genome assembly files
  annotation/        Genome annotation results
  mlst/              MLST typing results
  amr/               AMR gene detection
  virulence/         Virulence factor analysis
  serotype/          Serotyping results
  phylogroup/        Phylogenetic classification

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

Analysis completed successfully!

For questions or support:
  BioNXA Platform: https://bionxa.com
  Documentation: /en/tutorials/genomic-characterization-upec

â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
